The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).
They administered the xylazine-based conjugates to mice and monitored how the mice moved and breathed when they were later ...
Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism (1). The research paper validates the ...
In a study published in Cell Host & Microbe, a research team has demonstrated the causal link between microbial factors and ...
Perhaps the most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are enormously elevated in HF. Acutely, and if the ...
Perhaps the most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are enormously elevated in HF. Acutely, and if the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback